Bioethics News

Clinical Trials Not Immune from Poor Quality Drugs

(Wellcome Trust) – Substandard medicines (due to errors in factory production) and falsified medicines (due to criminal fraud) are profoundly neglected global health problems. Poor quality drugs have the potential to deny patients and their families the full and expected benefits of modern medicine. Global and national health policy decisions are often made using evidence generated from clinical trial reports. Until recently it was believed that trials were immune from the issue of medicine quality.

The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.